SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oxford GlycoSciences Plc

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jongmans who started this subject2/26/2003 10:25:51 AM
From: scaram(o)uche   of 469
 
Proteomics 2003 Feb;3(2):122-8

Peptidomics: A new approach to affinity protein microarrays.

Scrivener E, Barry R, Platt A, Calvert R, Masih G, Hextall P, Soloviev M, Terrett J.

Oxford GlycoSciences, Abingdon, Oxon, UK.

Protein microarrays for diagnostic and proteomic analyses are being developed using a number of different techniques for each of the steps required including immobilisation methods, assay and detection systems. This is extremely different to the development of DNA microarrays which is now a well established technology that has demonstrated the capabilities of transcriptomics to deliver validated differential transcripts. As mRNA and protein levels do not always correlate, protein microarrays would seem to be an obvious successor to DNA arrays. Unlike nucleic acids, however, protein targets are typically nonhomogeneous in physicochemical properties and affinity capture agents are often poorly characterised making the experiments difficult to perfect and reproduce. Moreover, running multiple affinity assays in parallel (multiplexing) is compromised by the heterogeneity of antibody affinities to their protein targets. In the peptidomic approach presented here the assayed mixture of proteins is enzymatically digested prior to affinity capture to form a mixture of short peptides that are more similar in their physicochemical properties than intact proteins. These peptides can be predicted by in silico digestion of individual proteins, e.g. from protein databases allowing design of nonhomologous reagents for the screening of affinity agent libraries. The use of mass spectrometry (e.g. matrix-assisted laser desorption/ionization-time of flight mass spectrometry) for a direct confirmation of the identity of the species captured, provides a further advantage compared to the more usual method of detection in which fluorescently labelled captured species are scanned to give a spatially resolved image of the array.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext